menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Vertex Gets UK MHRA Nod For Alyftrek In Cystic Fibrosis

    BUSINESSWIRE

    CHMP Backs KAFTRIO Label Expansion For Cystic Fibrosis Rare Mutations

    BUSINESSWIRE

    Vertex axes Verve gene editing pact amid shift in R&D priorities

    FIERCE BIOTECH

    Vertex to Participate in Upcoming March Investor Conferences

    BUSINESSWIRE

    Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand

    REUTERS

    Vertex challenger Sionna prices $191M IPO

    BIOPHARMADIVE

    CenExel Celebrates FDA Approval of Journax

    ACCESSWIRE

    US FDA approves Vertex`s non-opioid painkiller

    FDA

    Vertex Secures CASGEVY Reimbursement For Sickle Cell In England

    BUSINESSWIRE

    Vertex Updates Pipeline & Business Ahead Of Investor Meetings

    BUSINESSWIRE

    Vertex, Zai Lab Partner To Treat Autoimmune Diseases In Asia

    BIOSPECTRUM

    Orna, Vertex Partner On SCD And TDT Next-Gen Therapies

    PR NEWSWIRE

    Vertex to Present at 43rd Annual J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    FDA approves Vertex Pharma`s triple combo cystic fibrosis treatment

    REUTERS

    Vertex Announces FDA Approval for Trikafta to Non-F508del Variants

    BUSINESSWIRE

    Vertex Dips on Mixed Ph 2 Data for Non-Opioid Pain Therapy

    BIOSPACE

    Vertex`s pain prospect underwhelms versus placebo, sinking stock

    FIERCE BIOTECH

    Vertex, Saudi Arabia ink MoU to boost gene therapy production

    FIERCE PHARMA

    Vertex Presents Long-Term Data On Casgevy at ASH Annual Meeting

    BUSINESSWIRE

    Orsini Distributes CASGEVY® Gene-Editing Therapy

    PR NEWSWIRE

    Vertex`s Casgevy breaks ground with 1st commercial infusions

    FIERCE PHARMA

    Vertex Reports Third Quarter 2024 Financial Results

    BUSINESSWIRE

    Vertex to Participate in Upcoming November Investor Conferences

    BUSINESSWIRE

    Undaunted Vertex closes in on FDA nod for non-opioid pain drug

    FIERCE BIOTECH

    Vertex Updates on Kidney Programs at ASN Annual Kidney Week

    BUSINESSWIRE

    Rectify drug repairs bile composition in mice with liver disease

    FIERCE BIOTECH

    Vertex pain data: Combo results, Vicodin miss and stellar safety

    FIERCE BIOTECH

    Vertex To Present Phase 3 Data On Suzetrigine At ASA Meeting

    BUSINESSWIRE

    Vertex To Announce Q3 2024 Results On November 4th

    BUSINESSWIRE

    Vertex survey delves into current difficulties in pain treatment

    FIERCE PHARMA

    Editas cashes in on Vertex Cas9 licensing agreement for $57M

    FIERCE BIOTECH

    Vertex Presents CF Data At North American Conference

    BUSINESSWIRE

    Vertex adds CDMO Lonza to Casgevy production network

    FIERCE PHARMA

    Vertex-CRISPR & Bluebird Begin Sickle Cell Gene Therapies

    BIOSPACE

    Vertex goes all in on September`s bumper awareness month push

    FIERCE PHARMA

    LinkedIn Post Lands Vertex In Hot Water With MHRA Over UK Ad Regulations

    FIERCE PHARMA

    UK`s NHS To Roll Out Vertex/CRISPR Gene Therapy For Rare Blood Disorder

    REUTERS

    US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says

    REUTERS

    Vertex lifts sales guidance as Casgevy launch picks up

    FIERCE PHARMA

    Vertex Reports Second Quarter 2024 Financial Results

    BUSINESSWIRE

    Vertex, beaten by rare disease again, drops 2 assets on growing discard pile

    FIERCE BIOTECH

    Vertex Raises Forecast On Strong Cystic Fibrosis Treatment Demand

    REUTERS

    FDA Accepts Vertex`s NDA For Suzetrigine For Moderate-To-Severe Acute Pain

    PRESS RELEASE

    Vertex mines for more gene editing riches with $15M Orum licensing deal

    FIERCE BIOTECH

    Orum Therapeutics And Vertex Sign Multi-Target License Agreement

    BUSINESSWIRE

    Genomics Plc Expands Drug Discovery Collaboration With Vertex

    PR NEWSWIRE

    Vertex sues US over fertility support program for Casgevy gene editing therapy

    REUTERS

    FDA Accepts Vertex`s NDA For Next-Gen Cystic Fibrosis Treatment

    BUSINESSWIRE

    Vertex to Announce Second Quarter 2024 Financial Results on August 1

    BUSINESSWIRE

    Vertex inks long-term access deal for CF meds in Englan

    FIERCE PHARMA

    Long-term data shows durability of Vertex`s gene therapy Casgevy

    FIERCE PHARMA

    Vertex to Participate in Upcoming June Investor Conferences

    BUSINESSWIRE

    Jennifer Schneider Elected to Vertex Board of Directors

    BUSINESSWIRE

    Tessera unveils promising in vivo gene editing for sickle cell in #ASGCT24

    ENDPTS

    With 64 centers activated, bluebird is ready to grow Lyfgenia

    FIERCE PHARMA

    Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia

    ENDPTS

    Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

    REUTERS

    Vertex Reports First Quarter 2024 Financial Results

    BUSINESSWIRE

    Vertex: EU Approval for KALYDECO® in Infants ?1 Month with CF

    BUSINESSWIRE

    As pharma eyes shiny obesity drugs, Vertex tops orphan drug list

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.